https://www.optimumcomms.com/wp-content/uploads/2023/02/Ionctura_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-11-03 09:26:012023-11-03 09:27:58iOnctura to Present Research on Roginolisib and IOA-359 at ASH
https://www.optimumcomms.com/wp-content/uploads/2023/06/Poolbeg_Logo_300x180px-80x80-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-11-03 09:14:122023-11-03 09:14:12Poolbeg Pharma plc – POLB 001 Data to be Presented at American Society of Hematology Annual Meeting
https://www.optimumcomms.com/wp-content/uploads/2023/10/Vicore_Pharma_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-11-02 10:29:362023-11-02 10:30:16Vicore Pharma: Interim report July-September 2023
https://www.optimumcomms.com/wp-content/uploads/2023/10/Mission_Therapeutics_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-11-02 08:45:092024-01-11 14:23:46Mission Therapeutics to Present Abstract at American Society of Nephrology (ASN) Kidney Week 2023
https://www.optimumcomms.com/wp-content/uploads/2023/07/IO-Biotech.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-11-01 13:01:322023-11-01 13:02:18IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
https://www.optimumcomms.com/wp-content/uploads/2023/02/StormTx_Logo_300-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-11-01 08:41:202023-11-01 08:41:20STORM Therapeutics Appoints Marguerite Hutchinson, J.D., as Chief Business Officer
https://www.optimumcomms.com/wp-content/uploads/2023/02/Ionctura_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-31 09:11:262023-11-03 09:38:19iOnctura announces FDA clearance of IND application for roginolisib, a first-in-class allosteric modulator of PI3Kδ
https://www.optimumcomms.com/wp-content/uploads/2023/07/Leucid_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-31 08:37:012023-10-31 08:37:01Leucid Bio to Participate in Upcoming Healthcare Conferences
https://www.optimumcomms.com/wp-content/uploads/2023/02/FM_Logo_300px.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-25 12:39:532023-10-25 12:39:53Futura Medical Granted Marketing Authorisation for Eroxon® in Mexico
https://www.optimumcomms.com/wp-content/uploads/2023/08/Invizius_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-24 09:53:552023-10-24 09:53:55Invizius Announces Appointment of World-Renowned Nephrologist Professor Bernard Canaud to its Clinical Advisory Board
https://www.optimumcomms.com/wp-content/uploads/2023/07/Template_Logo_300x180px-80x80Web_Logos-4.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-24 08:43:362023-10-24 08:44:22Astraveus awarded €10.4 million grant by the French government as part of France 2030 investment plan
https://www.optimumcomms.com/wp-content/uploads/2023/07/IO-Biotech.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-23 08:06:042023-10-23 08:06:04Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology (ESMO) Congress
https://www.optimumcomms.com/wp-content/uploads/2023/08/Lytix_Biopharma_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-23 08:04:352023-10-23 08:04:35Encouraging preliminary data from Lytix Biopharma’s ATLAS-IT-05 study presented at ESMO 2023
https://www.optimumcomms.com/wp-content/uploads/2023/02/FM_Logo_300px.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-19 12:41:022023-10-25 12:45:39Futura Medical Launches Eroxon® in the United Arab Emirates
https://www.optimumcomms.com/wp-content/uploads/2023/08/4SC_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-19 10:58:172023-10-19 10:58:174SC provides Q3 highlights and financial forecast
https://www.optimumcomms.com/wp-content/uploads/2023/02/Ionctura_Logo_300px-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-19 08:40:272023-10-19 08:40:27New Research Highlights Potential of iOnctura Strategy Combining Autotaxin and TGF-Β Inhibitors In Cancer
https://www.optimumcomms.com/wp-content/uploads/2023/08/4SC_Logo_300x180px-80x80Web_Logos-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-18 09:08:342023-10-18 09:08:344SC receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL in the European Union
https://www.optimumcomms.com/wp-content/uploads/2023/08/Lytix_Biopharma_Logo_300x180px-80x80Web_Logos.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-17 08:44:592023-10-17 08:44:59Lytix Biopharma granted up to NOK14.3m (US$1.3m) of public non-dilutive funding from ’SkatteFUNN’
https://www.optimumcomms.com/wp-content/uploads/2023/02/AMSilk_Logo_300px-2.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-17 08:42:422023-10-17 08:42:42AMSilk appoints Gudrun Vogtentanz as Chief Scientific Officer
https://www.optimumcomms.com/wp-content/uploads/2023/02/StormTx_Logo_300-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2023-10-17 08:42:252023-10-17 08:42:25STORM Therapeutics Presented Novel Pre-Clinical Data on STC-15 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsFor more information about Optimum Strategic Communications, please get in touch.
